RecruitingNot ApplicableNCT06424015

Insulin and Insulin Pulses During Fasting

Effect of Insulin and Insulin Pulses on Fasting Glucagon Secretion and on Glucose Metabolism in Subjects Without Type 2 Diabetes


Sponsor

Mayo Clinic

Enrollment

60 participants

Start Date

Sep 15, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Fasting hyperglycemia contributes disproportionately to nonenzymatic glycosylation and the microvascular complications of type 2 diabetes. However, little is known about the regulation of glucose concentrations in the fasting state relative to what is known about the postprandial state. The proposed experiment is part of a series of experiments designed to establish how glucagon and insulin interact with their receptors to control fasting glucose in health and in prediabetes.


Eligibility

Min Age: 25 YearsMax Age: 65 Years

Inclusion Criteria1

  • people with normal or impaired fasting glucose and normal or impaired glucose tolerance

Exclusion Criteria8

  • HbA1c \> 6.5%
  • BMI ≥ 35 Kg/M2
  • Use of any glucose-lowering agents including metformin or sulfonylureas.
  • For female subjects: positive pregnancy test at the time of enrollment or study
  • History of prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty and vagotomy.
  • Active systemic illness or malignancy.
  • Symptomatic macrovascular or microvascular disease.
  • Hematocrit \< 35%

Interventions

OTHERIntralipid and heparin

Intralipid (20%, 0.011ml/kg/min; Baxter, Healthcare, Deerfield, IL) and heparin (200 units prime, 0.2 unit/kg/min continuous) will be infused to induce acute insulin resistance

OTHERSaline

Saline will be infused


Locations(1)

Mayo Clinic in Rochester

Rochester, Minnesota, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06424015


Related Trials